Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile

MT Newswires Live

01/06

Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.

The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'

Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.

The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.

Shares of the company were up 3.4% in recent Tuesday premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601937897"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601937897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601937897?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601937897","market":"hk","top_or_hot":-1,"title":"Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-06 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601937897","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601937897","pubTimestamp":1767704534,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aclaris Therapeutics  said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4006":"钢铁","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4187":"航天航空与国防","ACRS":"Aclaris Therapeutics","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","ATI":"阿利根尼","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"Aclaris Therapeutics表示皮炎候选疗法ATI-052的1期试验显示出“强大的安全性”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATI":1.5,"ACRS":1.5},"content_text":"Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}